News
GBIO
3.010
+0.67%
0.020
GENERATION BIO ANNOUNCES THE ACCEPTANCE OF FIVE ABSTRACTS AND AN INVITED ORAL PRESENTATION AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 27TH ANNUAL MEETING
Reuters · 3d ago
Weekly Report: what happened at GBIO last week (0415-0419)?
Weekly Report · 3d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
Weekly Report: what happened at GBIO last week (0408-0412)?
Weekly Report · 04/15 09:19
Generation Bio Price Target Maintained With a $10.00/Share by Needham
Dow Jones · 04/10 10:31
Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)
TipRanks · 04/10 10:30
Needham Reiterates Buy on Generation Bio, Maintains $10 Price Target
Benzinga · 04/10 10:24
Weekly Report: what happened at GBIO last week (0401-0405)?
Weekly Report · 04/08 09:20
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Biomea Fusion, BlackRock, Capital Bancorp and 3M among companies. JP Morgan raises target price to $767 from $742 for BlackRock. 3M Co, Advance Auto Parts and AIG among companies with target price cuts.
Reuters · 04/02 07:59
GENERATION BIO CO <GBIO.O>: JEFFERIES RAISES TARGET PRICE TO $6 FROM $5
Reuters · 04/02 04:41
Weekly Report: what happened at GBIO last week (0325-0329)?
Weekly Report · 04/01 09:19
Weekly Report: what happened at GBIO last week (0318-0322)?
Weekly Report · 03/25 09:20
Weekly Report: what happened at GBIO last week (0311-0315)?
Weekly Report · 03/18 09:19
Weekly Report: what happened at GBIO last week (0304-0308)?
Weekly Report · 03/11 09:19
Generation Bio GAAP EPS of -$0.53
Generation Bio Co. Reports Q4 GAAP EPS of -$0.53. Cash, cash equivalents and marketable securities were $264.4 million as of December 31, 2023, compared to $279.1 million in 2022. The company expects to report a quarterly profit of $0.07 per share.
Seeking Alpha · 03/07 16:29
Analysts Are Bullish on Top Healthcare Stocks: Generation Bio (GBIO), PepGen Inc. (PEPG)
Generation Bio has an analyst consensus of Strong Buy, with a price target consensus of $6.67. PepGen Inc. Has a Strong Buy rating and a $20.00 price target. Two analysts have maintained Buy ratings on the Healthcare sector stocks. The company's shares closed at $15.41 today.
TipRanks · 03/07 13:30
Generation Bio Price Target Maintained With a $5.00/Share by Wedbush
Dow Jones · 03/07 13:28
Wedbush Reiterates Outperform on Generation Bio, Maintains $5 Price Target
Benzinga · 03/07 13:18
Analysts’ Top Healthcare Picks: Generation Bio (GBIO), Curaleaf Holdings (CURLF)
TipRanks · 03/07 12:00
Generation Bio Price Target Cut to $10.00/Share From $14.00 by Needham
Dow Jones · 03/07 11:56
More
Webull provides a variety of real-time GBIO stock news. You can receive the latest news about Generation Bio Co. through multiple platforms. This information may help you make smarter investment decisions.
About GBIO
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.